Detalhe da pesquisa
1.
Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.
Diabetes Obes Metab
; 25(2): 491-500, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36251282
2.
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK.
Diabetes Ther
; 14(6): 1005-1021, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37120480
3.
Evaluating the Clinical and Economic Outcomes Associated with Poor Glycemic Control in People with Type 1 Diabetes in the Netherlands.
Clinicoecon Outcomes Res
; 15: 87-96, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36778040
4.
The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.
Eur J Health Econ
; 24(6): 895-907, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36114904
5.
Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.
J Med Econ
; 26(1): 1019-1031, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37525970
6.
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
Diabetol Metab Syndr
; 14(1): 32, 2022 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35164855
7.
The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
Adv Ther
; 39(7): 3180-3198, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35553372
8.
The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.
Diabetes Res Clin Pract
; 175: 108759, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33744377
9.
Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
Adv Ther
; 37(10): 4427-4445, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32862365
10.
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Adv Ther
; 37(5): 2427-2441, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32306244
11.
Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
J Med Econ
; 23(2): 193-203, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31613199
12.
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
Diabetes Ther
; 11(1): 259-277, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31833042
13.
The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain.
Diabetes Ther
; 11(2): 509-521, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31925724
14.
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
J Med Econ
; 23(11): 1311-1320, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32746676
15.
Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.
Diabetes Ther
; 10(1): 159-176, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30535837
16.
The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Adv Ther
; 36(8): 2034-2051, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31168765
17.
Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
BMJ Open Diabetes Res Care
; 7(1): e000705, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31641522
18.
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
Adv Ther
; 36(12): 3483-3493, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31650514